Tag
A massive systematic review of 5.5 million patients reveals that those with mental disorders receive significantly lower quality diabetes care, including less frequent monitoring and a 74% lower likelihood of being prescribed GLP-1 receptor
The Diabetes Endothelial Keratoplasty Study (DEKS) confirms that donor diabetes status has no clinically significant impact on 1-year graft success rates or endothelial cell loss after Descemet membrane endothelial keratoplasty (DMEK), faci
A post-hoc analysis of the CANVAS and CREDENCE trials reveals that the kidneyintelX.dkd score significantly improves risk reclassification and monitors the therapeutic impact of canagliflozin in patients with type 2 diabetes and chronic kid
A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immu
A prospective ARIC cohort study reveals that diabetes fundamentally modifies the relationship between the triglyceride-glucose (TyG) index and subclinical myocardial injury, shifting the risk profile from an L-shaped to a J-shaped associati
This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy’s cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.
Current evidence suggests minimal impact of omega-3 supplementation on neuropathy symptoms or quality of life in adults with diabetes.
This clinical trial evaluated monthly grocery vouchers for improving diabetes control in food-insecure patients, finding increased self-reported fruit and vegetable intake but no significant HbA1c improvement.
A 200‑patient cross‑sectional study found metformin use tripled the odds of vitamin B12 deficiency without affecting vitamins A, B1, B6, B9, C or E, highlighting the need for targeted B12 monitoring in long‑term metformin therapy.
A pan‑European analysis (n=5,550) found diabetes was associated with lower odds of amyloid and p‑tau pathology in cognitively impaired patients, but with markers of neurodegeneration (total tau, medial temporal atrophy) in cognitively norma
A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.
This review examines the first phase 3 randomized trial demonstrating that an AI-powered Diabetes Prevention Program lifestyle intervention is noninferior to human coaching in improving weight loss, HbA1c, and physical activity among adults
This meta-analysis of 36 cohort studies shows that higher triglyceride-glucose index levels predict increased risk of major adverse cardiovascular events in coronary heart disease patients, with differential effects observed by diabetes sta
The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.
A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.
A clinician-friendly summary of the American Diabetes Association’s 2024 Standards: who to screen, modern use of GLP‑1/GIP agents and SGLT2 inhibitors, continuous glucose monitoring, weight-management drugs, and implications for practice.
A case–control study reveals that elevated copper levels in diabetic pregnant women negatively affect newborn weight and head circumference, while chromium correlates positively with birth length. Smoking exposure adversely impacts infants’
A decade of research highlights cinnamon’s benefits in glycemic control, lipid modulation, anti-inflammatory effects, cognitive enhancement, and antimicrobial activity, supporting its adjunctive clinical use and revealing promising th
The PREVENT trial demonstrates that preventive PCI reduces adverse cardiac events in patients with vulnerable, non-flow-limiting coronary plaques, regardless of diabetes status, supporting a proactive interventional strategy alongside medic
A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.
